Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-L1 x LAG-3 bispecific antibody (Cellemedy)
- Development stage
- Preclinical
- Lead developer
- Cellemedy
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PD-L1 x LAG-3 bispecific antibody (Cellemedy) is an investigational bispecific monoclonal antibody designed to simultaneously target and inhibit the Programmed Death-Ligand 1 (PD-L1) and Lymphocyte-Activation Gene 3 (LAG-3) immune checkpoint pathways. Developed by Cellemedy, this therapeutic candidate aims to enhance anti-tumor T-cell activity by blocking two distinct inhibitory signals that contribute to immune evasion in the tumor microenvironment. Preclinical evaluations have demonstrated efficacy in melanoma models and a favorable safety profile in toxicity studies conducted at doses up to 200 mg/kg. The dual-targeting approach is intended to provide superior clinical outcomes compared to monotherapy by addressing multiple mechanisms of T-cell exhaustion and restoring the effector function of exhausted T cells.
- Other names
- PD-L1/LAG-3 bispecific antibodyCellemedy PD-L1 x LAG-3 bispecific antibody
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PD-L1 x LAG-3 bispecific antibody (Cellemedy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-L1 x LAG-3 bispecific antibody (Cellemedy).